Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen’s proprietary RenMice® platforms—including RenMab®, RenLite®, RenNano®, RenTCR™, and RenTCR mimic™—enable the discovery of fully human antibodies, bispecific ADCs, hu-VHHs, TCRs, and TCR mimic antibodies. Through RenSuper™ Biologics, the company provides global access to over one million fully human antibody sequences covering more than 1,000 targets. As of December 31, 2025, Biocytogen had established over 350 therapeutic antibody and clinical asset partnerships worldwide.Under its BioMice™ brand, Biocytogen offers thousands of animal and cell models, along with preclinical pharmacology and gene-editing services. Headquartered in Beijing, the company operates across China, the United States, and Germany.
